{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T19:44:38.910518+00:00","company":{"ticker":"ANIK","cik":898437,"company_name":"Anika Therapeutics, Inc."},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"8de475fcfb8cd98c9834db5b76d63b755d345f3b","cik":898437,"ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal year 2026","report_date":"2026-04-29","result_type":"guidance_update","revenue_text":"$114 to $122.5 million"},"claim":"Anika Therapeutics, Inc. reported fiscal year 2026 results: revenue $114 to $122.5 million. Guidance reaffirmed.","evidence_excerpt":"Fiscal 2026 Guidance Anika is maintaining the previously provided 2026 guidance: Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year Commercial Channel, $53 to $58 million, representing growth of 10% to 20% year over year OEM Channel, $61 to $64.5 million, flat to modestly lower year over year Adjusted EBITDA as a percent of revenue between 5% and 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-26-002799","anchor_url":"https://secwatch.observer/filing/0001171843-26-002799#claim-8de475fcfb8cd98c9834db5b76d63b755d345f3b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm"},{"fact_type":"earnings_release","fact_key":"37a708e2e24df3acbe979c6b508df07fa44127c8","cik":898437,"ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"eps_text":"($0.37) per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$5.1 million loss","period_text":"first quarter 2026","report_date":"2026-04-29","result_type":"reported_results","revenue_text":"$29.6 million"},"claim":"Anika Therapeutics, Inc. reported first quarter 2026 results: revenue $29.6 million, net income $5.1 million loss, EPS ($0.37) per diluted share.","evidence_excerpt":"First Quarter 2026 Continuing Operations Financial Summary Revenue $29.6 million, up 13% year over year Commercial Channel revenue $12.6 million, up 12% OEM Channel revenue $17.0 million, up 14% Gross margin 64.2% Operating expenses $24.5 million, including $4.9 million of one-time severance expenses GAAP loss from continuing operations $5.1 million, ($0.37) per diluted share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-26-002799","anchor_url":"https://secwatch.observer/filing/0001171843-26-002799#claim-37a708e2e24df3acbe979c6b508df07fa44127c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm"},{"fact_type":"executive_change","fact_key":"66d9944cf4","cik":898437,"ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Class II member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"Glenn R. Larsen resigned as Class II member of the Board at Anika Therapeutics, Inc..","evidence_excerpt":"On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the \"Board\") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the \"2026 Annual Meeting\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-26-002799","anchor_url":"https://secwatch.observer/filing/0001171843-26-002799#claim-66d9944cf4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm"},{"fact_type":"executive_change","fact_key":"2b475e0d08","cik":898437,"ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Class I member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"William R. Jellison resigned as Class I member of the Board of Directors at Anika Therapeutics, Inc..","evidence_excerpt":"On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the \"Board\") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the \"2026 Annual Meeting\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-26-002799","anchor_url":"https://secwatch.observer/filing/0001171843-26-002799#claim-2b475e0d08","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm"},{"fact_type":"executive_change","fact_key":"cf5d1165f7","cik":898437,"ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","filed_at":"2025-04-10T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-25","interim":false,"role":"Chief Operations Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Anne Nunes departed as Chief Operations Officer at Anika Therapeutics, Inc..","evidence_excerpt":"On April 4, 2025, Anika Therapeutics, Inc. (the “Company”) announced the departure of Anne Nunes, Chief Operations Officer, effective April 25, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-25-002148","anchor_url":"https://secwatch.observer/filing/0001171843-25-002148#claim-cf5d1165f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325002148/0001171843-25-002148-index.htm"},{"fact_type":"executive_change","fact_key":"eff6fd089c","cik":898437,"ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-05-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-28","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Joseph Capper was appointed as Director at Anika Therapeutics, Inc..","evidence_excerpt":"the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-24-003136","anchor_url":"https://secwatch.observer/filing/0001171843-24-003136#claim-eff6fd089c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/0001171843-24-003136-index.htm"},{"fact_type":"executive_change","fact_key":"db34e5b31e","cik":898437,"ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-05-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-28","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"William Jellison was appointed as Director at Anika Therapeutics, Inc..","evidence_excerpt":"the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-24-003136","anchor_url":"https://secwatch.observer/filing/0001171843-24-003136#claim-db34e5b31e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/0001171843-24-003136-index.htm"},{"fact_type":"executive_change","fact_key":"c16dd46b3a","cik":898437,"ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-05-02","interim":false,"role":"Executive Vice President, Chief Financial Officer and Treasurer","role_category":"cfo","successor_name":"Stephen Griffin","successor_named":true},"claim":"Michael Levitz resigned as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..","evidence_excerpt":"who tendered his resignation on May 2, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-24-002673","anchor_url":"https://secwatch.observer/filing/0001171843-24-002673#claim-c16dd46b3a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/0001171843-24-002673-index.htm"},{"fact_type":"executive_change","fact_key":"c942fdaf52","cik":898437,"ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-03","interim":false,"role":"Executive Vice President, Chief Financial Officer and Treasurer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Stephen Griffin was appointed as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..","evidence_excerpt":"announced that Stephen Griffin would be joining the Company as its Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-24-002673","anchor_url":"https://secwatch.observer/filing/0001171843-24-002673#claim-c942fdaf52","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/0001171843-24-002673-index.htm"},{"fact_type":"earnings_release","fact_key":"f11467729b54dc68eddd2d314cefb11622b60720","cik":898437,"ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":"$0.09 per diluted share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$(4.5) million, or ($0.31) per share","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$40.5 million"},"claim":"Anika Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $40.5 million, net income $(4.5) million, or ($0.31) per share, EPS $0.09 per diluted share. Guidance reaffirmed.","evidence_excerpt":"orthopedics, today reported financial results for its first quarter ended March 31, 2024. First Quarter 2024 Financial Summary Revenue in the first quarter of 2024 was $40.5 million, up 7% compared to $37.9 million in the first quarter of 2023. OA Pain Management revenue of $24.3 million, up 7% Joint Preservation and Restoration revenue of $13.8 million, up","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-24-002672","anchor_url":"https://secwatch.observer/filing/0001171843-24-002672#claim-f11467729b54dc68eddd2d314cefb11622b60720","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324002672/0001171843-24-002672-index.htm"}]}